What IR teams should plan for in 2H 2026 — conference calendar, NDR strategy, virtual/in-person mix, and the strategic themes shaping investor engagement.
A practical 2026 buyer’s guide for IR teams evaluating corporate access platforms — feature requirements, vendor comparison, implementation, and ROI calculation.
How EM corporate access works in 2026 — sovereign and corporate issuers, EM-focused funds, conference circuit, and the role of London and Singapore as gateway
A board-level framework for evaluating IR team performance through corporate access metrics — beyond meeting count, to coverage, conversion, and shareholder base outcomes.
Why healthcare and biotech corporate access works differently — JPM Healthcare Week, KOL meetings, scientific conferences, and the dedicated coverage ecosystem.
The compliance layer in modern corporate access — MiFID II inducement rules, MNPI risk, meeting documentation, and platform-level audit trails.
How sell-side conference allocation engines actually work — request scoring, issuer availability matching, fairness constraints, and the math behind 1-on-1 distribution.
The 8 corporate access metrics every IR team should track in 2026 — meeting volume, fund tier coverage, conversion, attribution, and engagement quality.
A practical corporate access playbook for small-cap IR teams — how to punch above weight with strategic conference selection, targeted NDRs, and platform-driven workflow.
The 2026 state of virtual corporate access — why hybrid is now default, how virtual meetings change fund coverage economics, and how WeConvene supports both
